Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1744. Epirubicin, as a Single Agent or in Combination, for Metastatic Breast Cancer

Epirubicin, as a Single Agent or in Combination, for Metastatic Breast Cancer

Cancer Care Ontario2003

1745. The Role of Aromatase Inhibitors in the Treatment of Postmenopausal Women with Metastatic Breast Cancer

The Role of Aromatase Inhibitors in the Treatment of Postmenopausal Women with Metastatic Breast Cancer

Cancer Care Ontario2003

1751. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. 12840087 2003 07 03 2003 07 08 2013 11 21 1533-4406 349 1 2003 Jul 03 The New England journal of medicine N. Engl. J. Med. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. 7-16 The use of high-dose adjuvant chemotherapy for high-risk primary breast cancer is controversial. We studied its efficacy in patients with 4 to 9 or 10 or more tumor-positive axillary lymph nodes (...) . Patients younger than 56 years of age who had undergone surgery for breast cancer and who had no distant metastases were eligible if they had at least four tumor-positive axillary lymph nodes. Patients in the conventional-dose group received fluorouracil, epirubicin, and cyclophosphamide (FEC) every three weeks for five courses, followed by radiotherapy and tamoxifen. The high-dose treatment was identical, except that high-dose chemotherapy (6 g of cyclophosphamide per square meter of body-surface area

NEJM2003

1752. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.

Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. 12840088 2003 07 03 2003 07 08 2013 11 21 1533-4406 349 1 2003 Jul 03 The New England journal of medicine N. Engl. J. Med. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. 17-26 The prognosis for women with primary breast cancer and 10 or more involved axillary (...) lymph nodes is poor. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation has been reported to be effective in the adjuvant setting for patients at high risk for relapse. We randomly assigned 540 female patients with primary breast cancer and at least 10 involved ipsilateral axillary lymph nodes to receive either six cycles of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) or the same adjuvant chemotherapy followed by high-dose chemotherapy

NEJM2003

1753. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. 12824205 2003 06 25 2003 07 08 2016 10 17 1538-3598 289 24 2003 Jun 25 JAMA JAMA Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. 3243-53 The Women's Health Initiative trial of combined estrogen plus progestin was stopped early when overall (...) health risks, including invasive breast cancer, exceeded benefits. Outstanding issues not previously addressed include characteristics of breast cancers observed among women using hormones and whether diagnosis may be influenced by hormone effects on mammography. To determine the relationship among estrogen plus progestin use, breast cancer characteristics, and mammography recommendations. Following a comprehensive breast cancer risk assessment, 16 608 postmenopausal women aged 50 to 79 years

JAMA2003

1754. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer.

A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. 12904519 2003 08 07 2003 08 13 2007 03 27 1533-4406 349 6 2003 Aug 07 The New England journal of medicine N. Engl. J. Med. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. 546-53 Although numerous studies have shown that the status of the sentinel node is an accurate predictor of the status of the axillary nodes in breast cancer, the efficacy (...) and safety of sentinel-node biopsy require validation. From March 1998 to December 1999, we randomly assigned 516 patients with primary breast cancer in whom the tumor was less than or equal to 2 cm in diameter either to sentinel-node biopsy and total axillary dissection (the axillary-dissection group) or to sentinel-node biopsy followed by axillary dissection only if the sentinel node contained metastases (the sentinel-node group). The number of sentinel nodes found was the same in the two groups

NEJM2003

1755. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. 14551341 2003 11 06 2003 11 10 2014 11 20 1533-4406 349 19 2003 Nov 06 The New England journal of medicine N. Engl. J. Med. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. 1793-802 In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy--but not tamoxifen therapy (...) of longer duration--prolongs disease-free and overall survival. The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy. We conducted a double-blind, placebo-controlled trial to test the effectiveness of five years of letrozole therapy in postmenopausal women with breast cancer who have completed five years of tamoxifen therapy. The primary end point was disease-free survival. A total of 5187 women were enrolled

NEJM2003

1756. Overview of the main outcomes in breast-cancer prevention trials.

Overview of the main outcomes in breast-cancer prevention trials. 12559863 2003 01 31 2003 02 12 2015 11 19 0140-6736 361 9354 2003 Jan 25 Lancet (London, England) Lancet Overview of the main outcomes in breast-cancer prevention trials. 296-300 Early findings on the use of tamoxifen or raloxifene as prophylaxis against breast cancer have been mixed; we update available data and overview the combined results. All five randomised prevention trials comparing tamoxifen or raloxifene with placebo (...) were included. Relevant data on contralateral breast tumours and side-effects were included from an overview of adjuvant trials of tamoxifen versus control. The tamoxifen prevention trials showed a 38% (95% CI 28-46; p<0.0001) reduction in breast-cancer incidence. There was no effect for breast cancers negative for oestrogen receptor (ER; hazard ratio 1.22 [0.89-1.67]; p=0.21), but ER-positive cancers were decreased by 48% (36-58; p<0.0001) in the tamoxifen prevention trials. Age had no apparent

Lancet2003

1757. Taxane containing regimens for metastatic breast cancer.

Taxane containing regimens for metastatic breast cancer. BACKGROUND: It is generally accepted that taxanes are among the most active chemotherapy agents in the management of metastatic breast cancer. OBJECTIVES: To identify and review the randomised evidence comparing taxane containing chemotherapy regimens with regimens not containing a taxane in the management of women with metastatic breast cancer. SEARCH STRATEGY: The specialised register maintained by the Editorial Base of the Cochrane (...) Breast Cancer Group was searched on 2nd May 2003 using the codes for "advanced breast cancer", "chemotherapy". Details of the search strategy applied by the Group to create the register, and the procedure used to code references, are described in the Group's module on the Cochrane Library. SELECTION CRITERIA: Randomised trials comparing taxane-containing chemotherapy regimens with regimens not containing taxanes in women with metastatic breast cancer. DATA COLLECTION AND ANALYSIS: Data were collected

Cochrane2003

1758. Regular self-examination or clinical examination for early detection of breast cancer.

Regular self-examination or clinical examination for early detection of breast cancer. BACKGROUND: Breast self-examination and clinical breast examination have been promoted for many years as general screening methods to diagnose breast cancer at an earlier stage in order to decrease morbidity and or mortality. The possible benefits and harms remain unclear. OBJECTIVES: To determine whether screening for breast cancer by regular self-examination or clinical breast examination reduces breast (...) cancer mortality and morbidity. SEARCH STRATEGY: The Cochrane Library and Medline were searched for randomised trials; date of last search October 2002. The specialised register maintained by the Cochrane Breast Cancer Group was searched. SELECTION CRITERIA: Randomised clinical trials, including cluster randomised trials. DATA COLLECTION AND ANALYSIS: Decisions on which trials to include were taken independently by the reviewers based on the methods of trial. Disagreements were resolved by discussion

Cochrane2003

1759. A gene-expression signature as a predictor of survival in breast cancer.

A gene-expression signature as a predictor of survival in breast cancer. BACKGROUND: A more accurate means of prognostication in breast cancer will improve the selection of patients for adjuvant systemic therapy. METHODS: Using microarray analysis to evaluate our previously established 70-gene prognosis profile, we classified a series of 295 consecutive patients with primary breast carcinomas as having a gene-expression signature associated with either a poor prognosis or a good prognosis. All (...) patients had stage I or II breast cancer and were younger than 53 years old; 151 had lymph-node-negative disease, and 144 had lymph-node-positive disease. We evaluated the predictive power of the prognosis profile using univariable and multivariable statistical analyses. RESULTS: Among the 295 patients, 180 had a poor-prognosis signature and 115 had a good-prognosis signature, and the mean (+/-SE) overall 10-year survival rates were 54.6+/-4.4 percent and 94.5+/-2.6 percent, respectively. At 10 years

NEJM2002

1760. Regular mammography use is associated with elimination of age-related disparities in size and stage of breast cancer at diagnosis.

Regular mammography use is associated with elimination of age-related disparities in size and stage of breast cancer at diagnosis. BACKGROUND: There is little consensus about recommending mammography for women 75 years of age and older. These women have mammography less frequently and are more likely to receive a diagnosis of advanced breast cancer. OBJECTIVE: To examine the relationship between use of screening mammography and size and stage of cancer at diagnosis in older women. DESIGN (...) : Retrospective cohort study. SETTING: Tumor registries in the Surveillance, Epidemiology, and End Results (SEER) program. PATIENTS: 12 038 women who were Medicare beneficiaries, were at least 69 years of age, resided in a SEER area, and received a new diagnosis of breast cancer in 1995 through 1996. MEASUREMENTS: Screening mammograms obtained in the 2 years before breast cancer diagnosis (none, one, or at least two) and stage and size of tumor at diagnosis. RESULTS: Older women (> or =75 years of age) had

Annals of Internal Medicine2002